FierceBiotechOriginal article
{"a":[{"_":"Agios says adios to sickle cell program over lackluster phase 2 data","$":{"href":"/biotech/agios-says-adios-sickle-cell-program-over-lackluster-phase-2-data","hreflang":"en"}}]}
Phase 2negativenext-generation pyruvate kinase activatorNegative
AI Analysis
Summary
Agios Pharmaceuticals discontinued development of its next-generation pyruvate kinase activator for sickle cell disease following lackluster Phase 2 data, marking the company's second indication discontinuation in two months.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Not Met
Outcome Details
Phase 2 study failed to support continued development; program discontinued
Importance:6/10
Sentiment:
-0.90
program discontinuationsickle cell diseasepyruvate kinase activatorfailed trial
Related Companies
Read the original article
Published by FierceBiotech on July 21, 2026 8:04 AM